Prediction of postoperative recurrences by gene expression profiling in patients with primary resected lung cancer

我们分析了LCNEC基因的表达、基因突变和已知分子靶点的免疫组织化学表达，并与肺腺癌的表达进行了比较。我们分析了13例原发LCNEC和14例腺癌(AC)。免疫组织化学(IHC)检测c-kit、人表皮生长因子受体2型(HER2)和血管内皮生长因子(VEGF)的表达，EGFR、K-ras和c-kit基因突变，荧光原位杂交(FISH)检测EGFR基因表达。在LCNEC中，c-kit、HER2和VEGF的IHC表达分别为76.9%、30.8%和100%。C-kit和HER2在LCNEC和AC中的表达差异有统计学意义。2例LCNEC存在HER2过表达，且AC组EGFR基因突变较大，LCNEC组仅发现1个EGFR突变(外显子18)。虽然免疫组化检测显示LCNEC中c-kit的表达水平较高，但未发现c-kit基因突变。这些发现提示抗血管内皮生长因子、抗c-kit和可能的抗HER2靶向药物在治疗LCNEC中具有潜在的作用。

We analyzed LCNEC gene expression, gene mutation and immunohistochemical expression of known molecular targets and compared expression to that of lung adenocarcinomas. We analyzed 13 patients with primary LCNEC and 14 patients with adenocarcinoma(AC). We evaluated immunohistochemical(IHC) expression for c-KIT, human epidermal growth factor receptor type 2(HER2), and vascular endothelial growth factor(VEGF), gene mutation for EGFR, K-ras and c-kit, and gene expression using fluorescence in situ hybridization(FISH) for EGFR. In cases with LCNEC, the IHC expression of c-KIT, HER2, and VEGF were 76.9%, 30.8%, and 100%, respectively. There was a significant difference in IHC expression in c-KIT and HER2 between LCNEC and AC. Two cases of LCNEC had overexpression of HER2, and EGFR gene mutation was greater in the AC group, with only a single EGFR mutation(exon 18) identified in the LCNEC group. Although LCNEC had a higher rate of expression of c-KIT by IHC, no c-kit gene mutations were found. These findings suggest a potential role for Anti-VEGF, Anti-c-KIT, and possibly Anti-HER2 targeted agents in the treatment of LCNEC.